Natraj Proteins re-appoints Sharad Kumar Jain as Executive Director

scanx
Reviewed by
Anirudha BScanX News Team
Key Highlights
  • Sharad Kumar Jain re-appointed as Whole-time Director and Executive Director effective October 1, 2026
  • Appointment approved for a period of three years during the 35th Annual General Meeting
  • Voting results showed 99.9999% support for all four resolutions passed at the meeting
  • Jain brings 39 years of experience in the soya industry and real estate business
powered bylight_fuzz_icon
52221175

*this image is generated using AI for illustrative purposes only.

Natraj Proteins Limited shareholders have approved the re-appointment of Sharad Kumar Jain as Whole-time Director and Executive Director. The appointment is effective from October 1, 2026, for a period of three years.

The decision was ratified during the company’s 35th Annual General Meeting held on September 29, 2026. All four resolutions placed before the shareholders were passed with the requisite majority, reflecting strong shareholder confidence in the current leadership structure.

Leadership continuity

Sharad Kumar Jain (DIN: 02757935) is one of the core promoters of the company. He holds a bachelor’s degree in science and brings 39 years of experience in the soya industry and real estate business. In his new role, he will be responsible for general business activities and assisting the Chairman & Managing Director.

The disclosure confirms that there are no relationships between directors relevant to this appointment. Additionally, it was stated that Jain is not debarred from holding the office of Whole-time Director by any SEBI order or other authority.

AGM outcomes and voting results

The meeting, conducted via Video Conferencing from the registered office in Itarsi, commenced at 2:00 pm and concluded at 2:20 pm. A quorum was established with 25 members participating through the virtual platform, satisfying the requirement of at least 15 members present.

The Board placed four items before the shareholders, including the adoption of financial statements for FY26 and other personnel appointments. The voting results were declared on September 29, 2026.

Resolution Votes Polled In Favour Against % In Favour
Item 1 (Ordinary) 13,49,289 13,49,288 1 99.9999%
Item 2 (Ordinary) 13,49,289 13,49,288 1 99.9999%
Item 3 (Ordinary) 13,49,289 13,49,288 1 99.9999%
Item 4 (Special) 13,49,289 13,49,288 1 99.9999%

Total shares outstanding stood at 37,47,000. The total votes polled across all resolutions represented approximately 36% of the outstanding share capital. CS Ishan Jain served as the scrutinizer for the voting process.

Historical Stock Returns for Natraj Proteins

1 Day5 Days1 Month6 Months1 Year5 Years
-0.97%-1.23%-0.82%+8.40%-0.32%-34.91%

How will Sharad Kumar Jain's continued leadership influence Natraj Proteins' strategic expansion in the soya processing sector over the next three years?

What specific operational efficiencies or cost-saving measures is the board expecting to see from the renewed executive mandate starting October 2026?

Given the low voter turnout of approximately 36%, what steps might the company take to improve shareholder engagement and liquidity in future AGMs?

Natraj Proteins turns profitable in FY26 with ₹113.51 lakh net profit

scanx
Reviewed by
Suketu GScanX News Team
Key Highlights
  • Natraj Proteins posted a net profit of ₹113.51 lakh in FY26, reversing a ₹146.27 lakh loss in FY25.
  • Revenue declined 14.1% to ₹10,112.13 lakh, while total expenditure fell 16.0%.
  • The 35th AGM is scheduled for September 29, 2026, via VC/OAVM.
  • Sharad Kumar Jain seeks re-appointment as Whole-time Director for three years.
powered bylight_fuzz_icon
50080642

*this image is generated using AI for illustrative purposes only.

Natraj Proteins reported a net profit of ₹113.51 lakh for the financial year ended March 31, 2026, reversing a net loss of ₹146.27 lakh in the previous year. Revenue from operations declined to ₹10,112.13 lakh from ₹11,778.29 lakh in FY25.

The company has scheduled its 35th Annual General Meeting (AGM) for Tuesday, September 29, 2026, at 2:00 pm via Video Conferencing or Other Audio-Visual Means (OAVM). Remote e-voting will commence on September 26, 2026, at 9:00 am and conclude on September 28, 2026, at 5:00 pm. The cut-off date for voting entitlement is September 22, 2026.

Financial Performance

The turnaround in profitability was driven by a reduction in total expenditure to ₹10,028.38 lakh from ₹11,944.78 lakh in FY25, despite the decline in revenue. Profit before tax stood at ₹110.58 lakh compared to a loss of ₹117.65 lakh in the prior year. Earnings per share (EPS) were ₹3.03, improving from a loss of ₹3.90 per share in FY25.

Metric FY26 FY25 Change
Revenue from Operations ₹10,112.13 lakh ₹11,778.29 lakh -14.1%
Total Expenditure ₹10,028.38 lakh ₹11,944.78 lakh -16.0%
Net Profit/(Loss) ₹113.51 lakh (₹146.27) lakh Turnaround
EPS (Basic) ₹3.03 (₹3.90) Improvement

Key Operational Updates

The Board proposes the re-appointment of Sharad Kumar Jain as Whole-time Director for three years w.e.f. October 1, 2026. Shareholders will also ratify the remuneration of M/s Yogesh Chourasia & Associates as Cost Auditors for FY27. Kailash Chand Sharma retires by rotation and offers himself for re-appointment as Chairman & Managing Director.

The company’s annual capacity remains at 75,000 M.T.P.A. for oilseed crushing and 15,000 M.T.P.A. for edible oil refining. No dividend is recommended for FY26 to retain profits for future purposes.

What the Numbers Show

The profit turnaround occurred despite a 14.1% decline in revenue, indicating significant cost efficiency improvements. Total expenditure fell by 16.0%, outpacing the revenue drop. This divergence suggests operational leverage or reduced input costs contributed more to the bottom line than top-line growth in FY26.

Historical Stock Returns for Natraj Proteins

1 Day5 Days1 Month6 Months1 Year5 Years
-0.97%-1.23%-0.82%+8.40%-0.32%-34.91%

What specific cost-cutting measures or operational efficiencies enabled Natraj Proteins to reduce total expenditure by 16% despite a 14% revenue decline?

How does the decision to retain all profits without declaring a dividend signal the company's strategic priorities for future expansion or debt reduction?

Will the re-appointment of Sharad Kumar Jain as Whole-time Director introduce new strategic initiatives to reverse the recent trend of declining operational revenue?

More News on Natraj Proteins

1 Year Returns:-0.32%